KREBS BIOCHEMICALS & INDUSTRIES
|
|
BOM : 524518     NSE : KREBSBIO     | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Upward Pledged Shares : None or < 25% |
Jun 09,2025 |
Price(EOD): ₹ 105.26
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 227.36 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
KREBS BIOCHEMICALS & INDUSTRIES | 27.5% | 22.1% | 20.7% |
SUN PHARMACEUTICAL INDUSTRIES | 0.3% | -4.9% | 15.8% |
DIVIS LABORATORIES | 0.2% | 10% | 53.5% |
CIPLA | 2.3% | 1.1% | 2.6% |
TORRENT PHARMACEUTICALS | 0.8% | -0.9% | 17.4% |
DR REDDYS LABORATORIES | 5.7% | 15% | 11.5% |
MANKIND PHARMA | -2.5% | -3.3% | 11.1% |
ZYDUS LIFESCIENCES | 3.3% | 10.1% | -7.4% |
LUPIN | 2% | -0.7% | 26% |
FUNDAMENTAL ANALYSIS OF KREBS BIOCHEMICALS & INDUSTRIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF KREBS BIOCHEMICALS & INDUSTRIES
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-8.42
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -26.94 Cr
[Latest Qtr - Mar2025 - Standalone Results ] -1.44
P/B Calculated based on Book Value of Rs -157.29 Cr
[Latest Year - Mar2025 - Standalone Results ] 5.24
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Mar2025 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA 114% 22% |
SHARE PRICE MOMENTUM OF KREBS BIOCHEMICALS & INDUSTRIES
KREBS BIOCHEMICALS & INDUSTRIES vs SENSEX
DEBT OF KREBS BIOCHEMICALS & INDUSTRIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
-1.62 -1.84 -1.91 -1.79 |
- - - - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF KREBS BIOCHEMICALS & INDUSTRIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Mar2025 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF KREBS BIOCHEMICALS & INDUSTRIES
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-46.8% -14.67% -6.64% -6.84% |
-49.05% -73.67% -41.13% -41.38% |
QtrlyTrend |
-8 | |
Latest Qtr: Mar2025 | ||
Quarterly Result Analysis → |
KREBS BIOCHEMICALS & INDUSTRIES related INDICES
You may also like the below Video Courses
FAQ about KREBS BIOCHEMICALS & INDUSTRIES
Is KREBS BIOCHEMICALS & INDUSTRIES good for long term investment?
As on Jun 09,2025, the Fundamentals of KREBS BIOCHEMICALS & INDUSTRIES look Poor and hence it may not be good for long term investment ! See Financial Performance of KREBS BIOCHEMICALS & INDUSTRIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is KREBS BIOCHEMICALS & INDUSTRIES UnderValued or OverValued?
As on Jun 09,2025, KREBS BIOCHEMICALS & INDUSTRIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES ?
As on Jun 09,2025, the Intrinsic Value of KREBS BIOCHEMICALS & INDUSTRIES is Rs. 67.72 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -76.97
Fair Value [Median EV / Sales Model] : Rs. 49.19
Fair Value [Median Price / Sales Model] : Rs. 86.26
Estimated Median Fair Value of KREBS BIOCHEMICALS & INDUSTRIES : Rs. 67.72
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.